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Objective: To determine the feasibility of introducing misoprostol as ﬁrst-line treatment for incomplete
abortion at a secondary-level health facility. Methods: An open-label prospective study was conducted in a
secondary-level health facility in Nigeria. Eligible women diagnosed with incomplete abortion received
400-μg sublingual misoprostol as ﬁrst-line treatment. Nurse–midwives took the lead in diagnosis, counseling,
treatment, and assessment of ﬁnal outcome. The primary outcome was the proportion of women who
completed the abortion process. Results: Complete evacuation was achieved in 83 of 90 (92.2%) eligible
women. The most common adverse effects were abdominal pain/cramps (58 [64.4%]), heavy bleeding
(21 [23.3%]), spotting (15 [16.7%]), and fever/chills (11 [12.2%]). More than 90% of women reported that the
procedure was satisfactory, that pain and adverse effects were tolerable, and that bleeding was acceptable.
Eighty-four (93.3%) and 86 (95.6%) women, respectively, would use themethod in the future and recommend
it to friends. Conclusion:Misoprostol is an effective, safe, and acceptable method for treating incomplete abor-
tion. It can be successfully used as ﬁrst-line treatment by nurse–midwives. Success rates over 90% are consis-
tent with ﬁndings from previous studies in which drug administration was controlled solely by physicians.
Clinical trials.gov: NCT01539408.
© 2012 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.1. Introduction
Restrictive abortion laws in Nigeria, as in most low-resource coun-
tries, continue to drive the high rates of unsafe abortion. Approxi-
mately 21.6 million unsafe abortions occur annually and almost all
of these take place in low-income countries [1]. Abortion-related
complications continue to make substantial contributions to maternal
morbidity and mortality in Sub-Saharan Africa [2–4].
The postabortion care model emerged in the 1990s as a means to
address complications related to unsafe abortion, especially in legally
restrictive settings [5]. One of the major advances in postabortion
care was the use of manual vacuum aspiration for uterine evacuation
when uterine size is consistent with fewer than 12 weeks of gestation
[6,7]. Major requisites for manual vacuum aspiration include avail-
ability of equipment and a skilled provider; these requirements are
major constraints to access in low-resource countries.
Misoprostol—a prostaglandin E1 analog—is cheap and heat stable,
making it attractive for use in the tropical conditions of Sub-Saharan
Africa. In recent years, several studies from Africa [8–14] and low-
resource settings in Latin America [15] and Asia [16] have shown15 E. 26th Street, New York,
8 1260.
eration of Gynecology and Obstetrics.misoprostol to be as effective as manual vacuum aspiration for the
treatment of incomplete abortion. Reported rates of completed abortion
in these studies ranged from 84.4% to 100% [8–16].
Misoprostol was more frequently associated with higher rates of ad-
verse effects—namely, longer bleeding after treatment, nausea, vomiting,
and fever [12]. However, at 1-week follow-up, the majority of women
who usedmisoprostol reported these effects to be easily tolerable [8,12].
Misoprostol treatment is also reported to be associated with high
levels of satisfaction and acceptability; many women who used miso-
prostol would prefer to use it in the future and would recommend it
to friends [8–15]. Consequently, misoprostol for treatment of incom-
plete abortion is considered to be an effective, safe, and acceptable alter-
native to manual vacuum aspiration. Furthermore, 400-μg sublingual
misoprostol and 600-μg oral misoprostol have been reported to have
similar safety and effectiveness proﬁles [11].
The American Congress of Obstetricians and Gynecologists (ACOG)
recommends that “misoprostol must be readily available especially
for women who do not otherwise have access to post-abortion care”
[17]. WHO has also included misoprostol as an essential drug for the
treatment of incomplete abortion in the ﬁrst trimester [18]. In light
of available evidence and recommendations, urgent steps are required
to scale-up and expand to primary and secondary levels of care the
use of misoprostol for treatment of incomplete abortion in order to
increase access among women in Africa.Published by Elsevier Ireland Ltd. All rights reserved.
Table 1
Demographic characteristics of participants (n=90).
Characteristic No. (%)
Agea, y (n=88)
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research—was to assess the feasibility of introducing misoprostol
as ﬁrst-line treatment for women with incomplete abortion at a
secondary-level health facility in southwestern Nigeria.≤20 7 (7.9)
21–25 13 (14.7)
26–30 35 (39.7)
31–35 19 (21.6)
≥36 14 (15.9)
Parity
0 2 (2.2)
1–2 36 (40.0)
3–4 31 (34.4)
≥5 19 (21.1)
Marital status
Single 7 (7.8)
Married 82 (91.1)
Divorced 1 (1.1)
Education
None 1 (1.1)
Primary 15 (16.7)
Secondary 49 (54.4)
Tertiary 25 (27.8)
Occupation
Unemployed 3 (3.3)
Student 6 (6.7)
Housewife 4 (4.4)
Self-employed 51 (56.7)
Employed 26 (28.9)
a Mean age, 30.6±5.7 years.
Table 2
Symptoms reported by women after administration of misoprostol (n=90).
Symptom No. (%)
Cramping/abdominal pain 13 (14.4)
Vomiting 2 (2.2)
Fever/chills 2 (2.2)
Profuse bleeding 1 (1.1)
Nausea 4 (4.4)
Diarrhea 1 (1.1)
Increased bleeding (but not profuse) 10 (11.1)2. Materials and methods
An open-label prospective study was conducted at the Adeoyo Ma-
ternity Hospital—a secondary level health facility in Ibadan, Nigeria—
between August 1, 2009, and October 27, 2010.
Incomplete abortion was deﬁned as past or present history of
vaginal bleeding and evidence of an incomplete abortion with sub-
stantial debris in the uterus if ultrasound was used or, if no ultrasound
was used, past or present history of vaginal bleeding during pregnancy
and an open cervical os. Women presenting to the hospital who lived
or worked within 1 hour of the facility and who had a conﬁrmed
incomplete abortion were invited to participate in the study once it
had been determined that theywould be advised to undergo a surgical
evacuation based on the standard practice at the hospital.
Women were eligible to participate in the study if they had no con-
traindications tomisoprostol: uterine sizewas not consistentwithmore
than 12 weeks of gestation; there were no signs of severe infection
(deﬁned as at least 1 of the following: foul-smelling discharge; fever
above 38 °C; and uterine tenderness); theywere hemodynamically sta-
ble (pulse b110 per minute and systolic blood pressure≥100 mmHg);
theywere in general good health; and theywerewilling to provide con-
tact information for the purposes of follow-up. Women were excluded
if they had an intrauterine device in place, were suspected of having
an ectopic pregnancy, or were younger than 18 years of age and had
no accompanying adult to provide informed consent. Written informed
consent was obtained from all participants. Ethics approval for the
study was obtained from the Oyo State Ethical Review Committee.
The research nurse gave 400-μg sublingual misoprostol (Cytotec;
Pﬁzer, New York, NY, USA) to all participants. The women were
counseled about adverse effects and postabortion contraception, and
were discharged from the hospital after a minimum 2-hour period of
observation. Prior to discharge, participants were given a prescription
of paracetamol tablets for pain relief, if required.
Participants were requested to return to the clinic 1 week later to
conﬁrm their clinical status. In the event of continued heavy bleeding,
enlargeduterus, or suspicion of ectopic pregnancy,womenwere referred
for ultrasound and follow-up care. In the event of continued incomplete
abortion, women were given the option of immediate surgical evacua-
tion or return for additional follow-up in 1 week to see whether expul-
sion would occur spontaneously. If abortion was not complete after the
second follow-up visit, surgical completion was performed.
Research nurses were responsible for recruitment, diagnosis of in-
complete abortion, counseling for participation in the study, adminis-
tration of the drug, and follow-up. The performance of these leading
roles by research nurses was speciﬁc to the present study; normally,
they would be carried out by physicians. Physicians were, however,
available for consultation if needed.
All women were advised to return to the hospital at any time if com-
plications arose or if they had questions. Theywere also given telephone
numbers of research team members to call if needed. At the follow-up
visits,womenunderwent physical examination andwere askedwhether
they thought the abortion was complete, what their level of satisfaction
was, and whether they would use the method again. Research team
members, trained to maintain conﬁdentiality, conducted home visits to
trace participants who failed to return for the follow-up visits.
The intention was to include all consenting eligible women during
the study period. Data entry was performed with Excel version 11
(Microsoft, Redmond, WA, USA) and analysis was carried out using
SAS version 8 (SAS Institute, Cary, NC, USA) via χ2 test. The level of
statistical signiﬁcance was set at Pb0.05.3. Results
In total, 90 eligible women consented to participate and were
recruited into the study. The demographic proﬁle of the women is
shown in Table 1. The mean age of the participants was 30.6±
5.7 years, and 49 (54.4%) women had received secondary-level edu-
cation. The median duration of stay following misoprostol adminis-
tration was 2.0 hours (range, 0.5–48 hours).
Cramping/abdominal pain and increased vaginal bleeding were the
symptoms most commonly reported by women shortly after adminis-
tration of misoprostol (Table 2). All participants were followed-up. At
the 1-week follow-up, 76 (84.4%) women reported completion of the
abortion process. In total 7 (7.8%) women underwent surgical interven-
tion. Of the 7 womenwho had surgical intervention, 4 with ongoing in-
complete abortion requested surgical evacuation before the scheduled
1-week follow-up because of heavy bleeding; the remaining 3 women
had surgical evacuation for persistent bleeding after the second
follow-up visit (i.e. 2 weeks after misoprostol administration). Six
(6.7%) women made unscheduled calls to investigators, and 4 (4.4%)
made unscheduled visits to the hospital (Table 3). The reasons for
these calls and visits were spotting and bleeding. The research nurses
reinforced information previously provided to thewomen and reassured
them that these effects were to be expected.
At follow-up, most women experienced adverse effects following
the use of misoprostol (Table 4). Abdominal pain/cramps, bleeding,
and fever/chills were the most common adverse effects reported.
Table 3
Outcomes and service delivery (n=90).a
Value
Outcome
Complete abortion at 1-week follow-up 76 (84.4)
Complete abortion at 2-week follow-up 83 (92.2)
Surgical intervention 7 (7.8)
Participant requested surgical intervention
before 1-week follow-up
4 (4.4)
Service delivery
Made unscheduled visit to hospital 4 (4.4)
Made unscheduled call to clinic 6 (6.7)
Median duration of hospitalization following
misoprostol administration, h
2.0 (0.5–48.0)
a Values are given as number (percentage) or median (range).
Table 5
Participant reports of satisfaction and acceptability.
No. (%)
Reported satisfaction with the procedure
Unsatisfactory 4 (4.4)
Satisfactory 47 (52.2)
Very satisfactory 39 (43.3)
Acceptability of bleeding
Very unacceptable 4 (4.4)
Unacceptable 3 (3.3)
Acceptable 67 (74.4)
Very acceptable 16 (17.8)
Perception of pain associated with misoprostol use
No pain 6 (6.7)
Intolerable 4 (4.4)
Tolerable 74 (82.2)
Very tolerable 6 (6.7)
Perception of adverse effects
Very severe 1 (1.1)
Severe 7 (7.8)
Tolerable 74 (82.2)
Easily tolerable 8 (8.9)
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47 (52.2%) were satisﬁed and 39 (43.3%) were very satisﬁed (Table 5).
In total, 67 (74.4%) women considered the bleeding to be acceptable
and 16 (17.8%) rated it as very acceptable. Only 3 (3.3%) and 4 (4.4%)
participants reported the bleeding to be unacceptable and very
unacceptable, respectively (Table 5). Of the 7 women who underwent
surgical evacuation, 2 reported the bleeding associated with miso-
prostol to be unacceptable. Pain associated with misoprostol use
was tolerable for 74 (82.2%) women and very tolerable for 6 (6.7%)
women (Table 5). Six (6.7%) women experienced no pain and 4 (4.4%)
considered the pain to be intolerable.
In total, 74 (82.2%) and 8 (8.9%) participants reported that adverse
effects were tolerable and easily tolerable, respectively (Table 5).
Seven (7.8%) women reported the adverse effects to be severe and 1
(1.1%) woman perceived them to be very severe. Fifty-nine (65.6%)
women said that they would have felt comfortable taking the medica-
tion at home (P=0.003). Eighty-four (93.3%) participants would
select the method if they experienced an abortion in the future
(Pb0.0001) and 86 (95.6%) would recommend the method to their
friends (Pb0.0001).
4. Discussion
Access to postabortion care services in low-resource countries is
limited by a combination of factors. In addition to restrictive abortion
laws, high costs and weak health infrastructure (which manifests
as poorly equipped health facilities and lack of skilled personnel) are
some of the major issues. Inequitable distribution of health personnel
also depriveswomen in rural areas access to skilled providers.Measures
are, therefore, required to increasewomen's access to postabortion care
services in order to help reduce the substantial contribution of unsafe
abortion to maternal morbidity and mortality.
The present study was implemented in the typical clinical setting
of a secondary health facility. Nurses had prominent roles in the
study. The ﬁndings conﬁrm the high success rates attributed to miso-
prostol in randomized controlled trials conducted mainly in tertiary
health facilities [8–14]. The success rate may have been higher but
4 of the women did not wish to wait until the end of the ﬁrst week
of follow-up. High levels of tolerance of adverse effects, satisfactionTable 4
Adverse effects reported by participants at follow-up (n=90).
Adverse effect No. (%)
Heavy bleeding 21 (23.3)
Normal bleeding 48 (53.3)
Spotting (like menses) 15 (16.7)
Nausea 6 (6.7)
Vomiting 4 (4.4)
Pain/cramps 58 (64.4)
Fever/chills 11 (12.2)with the procedure, and willingness to use the method in the future
or recommend it to friends also conﬁrm the reported acceptability,
safety, and effectiveness of misoprostol as an alternative treatment
to manual vacuum aspiration for incomplete abortion [8,10,12].
The ﬁndings also justify the calls for decentralization of postabortion
care in Africa [19]. Nurses are more widely distributed than medical
doctors and, thus, are closer to women in the community. With proper
training, nurses can competently provide effective postabortion care
services, thereby increasing access among women in Africa [19]. ACOG
also supports the position that nurses can provide misoprostol as
ﬁrst-line treatment for incomplete abortion, even in outpatient settings,
provided they receive appropriate training and support [17].
Concerted efforts are needed to promote this approach and in-
crease its adoption, pushing for incorporation of misoprostol as treat-
ment for incomplete abortion in clinical protocols and guidelines.
Professional groups will have prominent roles in advocacy to ensure
its acceptance among policy makers across Africa. Public enlighten-
ment and community mobilization are crucial aspects in promoting
widespread acceptance.
The main strength of the present study was the setting in which it
was implemented. The health facility is typical of a secondary-level
facility in a low-resource country. Furthermore, all women recruited
to the study were followed-up and their perspectives documented.
The major limitation of the study was the small number of women;
however, the ﬁndings are consistentwith those fromprevious research.
The results of the present study reinforce the understanding that
misoprostol can be effectively used as ﬁrst-line treatment for incom-
plete abortion. Nurses are capable of providing misoprostol for in-
complete abortion—making it possible to recommend the adoption
of misoprostol as ﬁrst-line treatment by health systems in Africa, par-
ticularly in places where access to services is limited.
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